| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs | 1 | GlobeNewswire (USA) | ||
| 22.05. | Crinetics Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.05. | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts | 186 | GlobeNewswire (Europe) | SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel... ► Artikel lesen | |
| 14.05. | 18 Analysts Have This To Say About Crinetics Pharmaceuticals | 1 | Benzinga.com | ||
| 13.05. | Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 10.05. | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 145 | GlobeNewswire (Europe) | SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted... ► Artikel lesen | |
| 10.05. | Crinetics Pharmaceuticals Inc reports results for the quarter ended in January - Earnings Summary | 1 | Reuters | ||
| 09.05. | Crinetics Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.05. | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update | 195 | GlobeNewswire (Europe) | Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing's Syndrome Will be Presented at ENDO... ► Artikel lesen | |
| 08.05. | Crinetics Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.04. | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 92 | GlobeNewswire (Europe) | SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted... ► Artikel lesen | |
| 04.04. | Crinetics Pharmaceuticals, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 03.04. | Crinetics Pharmaceuticals gains amid pitch at Sohn charity conference | 3 | Seeking Alpha | ||
| 22.03. | Crinetics Pharmaceuticals director Fust sells shares worth over $2.6m | 2 | Investing.com | ||
| 20.03. | Crinetics Pharmaceuticals CFO sells shares worth nearly $300k | 2 | Investing.com | ||
| 19.03. | Crinetics Pharmaceuticals files to sell 8.33M shares of common stock for holders | 1 | Seeking Alpha | ||
| 19.03. | Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why | 1 | Benzinga.com | ||
| 19.03. | Crinetics Pharmaceuticals, Inc.: Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients | 77 | GlobeNewswire (Europe) | 56% of Participants on Paltusotine Achieved IGF-1 =1.0 xULN vs. 5% on Placebo (p Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned... ► Artikel lesen | |
| 12.03. | Crinetics Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | Crinetics Pharmaceuticals, Inc.: Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome | 38 | GlobeNewswire (Europe) | Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall... ► Artikel lesen |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NEL | 5.068 |
| EVOTEC | 3.484 |
| NVIDIA | 3.187 |
| VOLKSWAGEN | 2.493 |
| TUI | 2.186 |
| BAYER | 2.090 |
| SALESFORCE | 1.926 |
| GAMESTOP | 1.742 |
| BIONTECH | 1.709 |
| PLUG POWER | 1.650 |
| DELL TECHNOLOGIES | 1.537 |
| BYD | 1.274 |
| AIXTRON SE | 1.272 |
| RHEINMETALL | 1.175 |
| DEUTSCHE LUFTHANSA | 1.029 |
| SUPER MICRO COMPUTER | 1.021 |
| UIPATH | 983 |
| JINKOSOLAR | 912 |
| SIEMENS ENERGY | 807 |
| DEUTSCHE BANK | 798 |
| PALANTIR TECHNOLOGIES | 754 |
| HELLOFRESH | 748 |
| TESLA | 736 |
| MERCEDES-BENZ | 731 |
| BASF | 721 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
